Aarti Pharmalabs Q2 FY27 Results Due on October 28

Aarti Pharmalabs is scheduled to consider and approve its unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2026. The board meeting is set for Wednesday, October 28, 2026, according to the company's October 9 intimation to BSE. The update places the company among the early corporate reporters for the July-September quarter. The Q2 FY27 filing was marked as upcoming in the available results calendar, with the board meeting scheduled 28 days after the quarter ended. The results were not yet available on NSE at the time of the update. Investors will look for the reported financial statements and management commentary once the board completes its review.

Board to consider Q2 and half-year accounts

The board agenda covers unaudited standalone and consolidated financial results for Q2 FY27. It also covers the first half of FY27, which comprises the April-June and July-September quarters. The company informed BSE that the meeting would be held on October 28, 2026. This is the formal event that precedes the release of quarterly numbers to stock exchanges. No Q2 revenue, EBITDA, profit or earnings-per-share figure was included in the supplied pre-results information. As a result, the available data indicates a reporting date rather than a confirmed operating outcome for the September quarter.

Q2 filing date follows the September quarter end

The July-September 2026 period ended on September 30. The stated result date of October 28 puts the filing 28 days after the end of the quarter. The results calendar identifies this as Q2 FY27 and labels the event as upcoming. The prior reported earnings date was August 7, 2026, for the June quarter. The timing gives investors a clear reference point for when the company's second-quarter and first-half disclosures are expected. The official filing and exchange publication will remain the key documents for confirmed financial figures.

June quarter showed strong year-on-year growth

The most recent reported quarter in the supplied data was June 2026, or Q1 FY27. Consolidated sales were reported at ₹536 crore, compared with ₹386 crore in June 2025, representing growth of 39% year on year. EBITDA was ₹136 crore, up 43% from ₹95 crore a year earlier. Net profit was reported at ₹76 crore, compared with ₹50 crore in the corresponding quarter of the previous year. Earnings per share rose to ₹8.40 from ₹5.46. These figures form the immediate comparison base ahead of the Q2 announcement.

Sequential comparison provides additional context

Against the March 2026 quarter, June 2026 sales of ₹536 crore were lower than ₹583 crore. EBITDA increased from ₹113 crore in March 2026 to ₹136 crore in June 2026. Net profit increased from ₹61 crore to ₹76 crore over the same sequential comparison. EPS rose from ₹6.74 to ₹8.40. The mix of lower sequential sales and higher EBITDA and profit makes the upcoming Q2 disclosure relevant for assessing whether the June-quarter profitability trend continued.

Key reported financial figures

All absolute revenue figures in the table are presented in ₹ crore. The source also described June-quarter revenue as ₹5.36 billion, which is equivalent to ₹536 crore. The table reflects the consolidated June-quarter figures supplied ahead of the Q2 FY27 result date. It does not contain Q2 FY27 estimates or reported results. Any comparison with September-quarter numbers will be possible only after the company releases its financial statements.

Quarterly history shows revenue movement

The longer quarterly financial series supplied for Aarti Pharmalabs shows revenue of ₹388 crore in June 2025, ₹418 crore in September 2025, ₹437 crore in December 2025, ₹596 crore in March 2026 and ₹544 crore in June 2026. This series illustrates that quarterly revenue has varied over recent periods. It also shows a sharp increase between June 2025 and June 2026. The separate consolidated results summary cited ₹536 crore for June 2026, while the broader quarterly series cited ₹544 crore. Investors should rely on the final standalone and consolidated exchange filings for the applicable reported basis and exact comparatives.

Earnings call information needs confirmation

The supplied information contains differing references to the Q2 FY27 earnings call date. One notice refers to a call at 3:30 p.m. IST on October 28, 2026, while another update states that Aarti Pharmalabs scheduled the call for October 29, 2026, at 3:30 p.m. IST. The latter update says the discussion will cover Q2 and H1 FY27 operational and financial performance. Because the available references are not aligned, investors and analysts should check the final company communication, dial-in details or exchange announcement before joining. The call is expected to provide management's discussion of the released results and outlook.

What investors can assess after the release

The result filing will allow a comparison of September-quarter sales, EBITDA, net profit and EPS with the June 2026 base. It will also show the first-half FY27 performance, based on the April-September period. The June quarter delivered 39% sales growth and 54% net-profit growth year on year in the supplied consolidated summary. Whether those growth rates were sustained, improved or moderated in Q2 cannot be determined before the board-approved results are published. There is no share-price movement or market reaction data in the supplied information. Accordingly, the immediate market focus is likely to be on the official financial release rather than pre-result assumptions.

Why the Q2 update matters

Aarti Pharmalabs' Q2 FY27 announcement will provide the next confirmed view of its operating and financial performance after the June-quarter results. The June-quarter data showed higher EBITDA and net profit than both the March 2026 and June 2025 comparisons provided. The half-year statement will also give a broader view than a single quarter. The board is scheduled to consider the unaudited standalone and consolidated results on October 28, 2026. Investors can then review the exchange filing and the final earnings-call notice for reported figures, detailed financial statements and management commentary.